Partial lipodystrophy
MONDO:0027767Loss and redistribution of subcutaneous and/or visceral adipose tissue from specific regions of the body.
21 clinical trials for this condition and its sub-types, 7 tagged with Partial lipodystrophy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Partial lipodystrophy
-
Familial partial lipodystrophy 13 trials · 14 incl. sub-types
10 sub-types
- Familial partial lipodystrophy, Dunnigan type 4 trials
- AKT2-related familial partial lipodystrophy 0 trials
- CIDEC-related familial partial lipodystrophy 0 trials
- LIPE-related familial partial lipodystrophy 0 trials
- PLIN1-related familial partial lipodystrophy 0 trials
- PPARG-related familial partial lipodystrophy 0 trials
- Autosomal semi-dominant severe lipodystrophic laminopathy 0 trials
- Familial partial lipodystrophy, Kobberling type 0 trials
- Lipodystrophy, familial partial, type 8 0 trials
- Lipodystrophy, familial partial, type 9 0 trials
-
Acquired partial lipodystrophy 6 trials
-
Could blocking growth hormone ease severe insulin resistance?
Disease control Recruiting nowThis study tests a drug called pegvisomant in 25 adults with severe insulin resistance caused by lipodystrophy or insulin receptor gene changes. Participants give themselves daily shots for one month and have two hospital stays for tests. The goal is to see if blocking growth hor…
Phase 2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New registry tracks Real-World safety of rare disease drug metreleptin
Disease control Recruiting nowThis registry monitors the safety and effectiveness of metreleptin in up to 100 people with generalized or partial lipodystrophy who are already taking the drug in routine care. Researchers will track serious events like pancreatitis, liver problems, infections, and cancers. The …
Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Hope for rare fat disorder: new drug shows promise in Long-Term trial
Disease control Recruiting nowThis study looks at the long-term safety and effectiveness of a daily injection called metreleptin for people with familial partial lipodystrophy, a rare condition where fat is distributed abnormally. About 24 participants who completed a previous study will receive the drug for …
Phase 3 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Hope for rare fat disorder: expanded access to metreleptin offered
Disease control Expanded accessThis expanded access program provides metreleptin (MyaLept) to patients with familial partial lipodystrophy who also have diabetes or very high triglycerides. Metreleptin is already approved for generalized lipodystrophy, but this program aims to help those with the partial form.…
Sponsor: University of Michigan • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Could mounjaro help a rare fat disorder? new trial aims to find out
Disease control Recruiting nowThis phase 2 trial tests whether tirzepatide (Mounjaro), a drug already approved for diabetes and weight loss, can improve blood sugar and lower triglycerides in people with partial lipodystrophy—a rare condition where the body loses fat tissue. Researchers will compare tirzepati…
Phase 2 • Sponsor: University of Michigan • Aim: Disease control
Last updated Jun 26, 2026 14:27 UTC